MARKET

ATRC

ATRC

AtriCure
NASDAQ

Real-time Quotes | Nasdaq Last Sale

63.73
+1.08
+1.72%
After Hours: 63.73 0 0.00% 16:01 03/05 EST
OPEN
63.01
PREV CLOSE
62.65
HIGH
63.84
LOW
59.76
VOLUME
362.55K
TURNOVER
--
52 WEEK HIGH
68.00
52 WEEK LOW
23.17
MARKET CAP
2.90B
P/E (TTM)
-54.2337
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4)
Benzinga · 2d ago
Cardiac Ablation Market Share, Size and Analysis to Record Significant Growth Over 2020-2026 - Industry News
Mar 05, 2021 (Market Insight Reports) -- As per the report titled 'Cardiac Ablation Market Size By Product, By Application, By End-use, Industry Analysis...
Market Insight Reports · 2d ago
Endovenous Ablation Devices Market Size Research 2021: by Key Market Trends Evaluation, Supply Demand Scenario, Industry Forecast with Growth Prospects, Business Strategies with Share Outlook 2025
Mar 04, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Endovenous Ablation Devices...
The Express Wire · 3d ago
Left Atrial Appendage Closure Device Industry Share, Size 2021 Global Market Growth, Trends, Revenue, Top Manufacturers, Business Growth, Demand and Applications Research Report Forecast to 2026
Mar 03, 2021 (The Expresswire) -- “Final Report will add the analysis of the impact of COVID-19 on this industry." “ Left Atrial Appendage Closure Device...
The Express Wire · 4d ago
Atricure Inc Has Returned 69.5% Since SmarTrend Recommendation (ATRC)
SmarTrend identified an Uptrend for Atricure Inc (NASDAQ:ATRC) on November 13th, 2020 at $39.43. In approximately 4 months, Atricure Inc has returned 69.54% as of today's recent price of $66.84.
Comtex SmarTrend(R) · 4d ago
AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today...
BusinessWire - BZX · 5d ago
Endovenous Ablation Devices Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Mar 02, 2021 (Market Insight Reports) -- The Global Endovenous Ablation Devices Market is expected to grow at a CAGR of over 6% during the forecast period...
Market Insight Reports · 5d ago
The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 1)
Benzinga · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATRC. Analyze the recent business situations of AtriCure through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATRC stock price target is 70.14 with a high estimate of 78.00 and a low estimate of 65.00.
EPS
Institutional Holdings
Institutions: 298
Institutional Holdings: 48.01M
% Owned: 105.34%
Shares Outstanding: 45.57M
TypeInstitutionsShares
Increased
68
5.25M
New
63
2.07M
Decreased
58
5.46M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+2.73%
Healthcare Equipment & Supplies
+2.13%
Key Executives
Chairman/Independent Director
Scott Drake
President/Chief Executive Officer/Director
Michael Carrel
Chief Financial Officer/Senior Vice President
M. Andrew Wade
Chief Financial Officer
Angela Wirick
Chief Operating Officer
Douglas Seith
Senior Vice President/Director of Marketing
Justin Noznesky
Chief Technology Officer
Salvatore Privitera
Independent Director
Mark Collar
Independent Director
Daniel Florin
Independent Director
Regina Groves
Independent Director
B. Kristine Johnson
Independent Director
Mark Lanning
Independent Director
Karen Prange
Independent Director
Sven Wehrwein
Independent Director
Robert White
No Data
  • All
  • Financials
  • Insiders
More
About ATRC
AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA).

Webull offers kinds of AtriCure Inc. stock information, including NASDAQ:ATRC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATRC stock methods without spending real money on the virtual paper trading platform.